Enveda Therapeutics received FDA IND clearance and began dosing a Phase I study of ENV‑308, a once‑daily oral small molecule designed for chronic weight management. The start marks Enveda’s transition from discovery to clinical evaluation in obesity. Separately, Dexoligo Therapeutics presented data supporting DXO‑1801, a liver‑targeted siRNA candidate for inflammation‑driven anemia, showing preclinical promise in modulating hepcidin and iron availability. Both programs highlight continued investor and developer focus on metabolic and inflammation‑driven indications, with early‑stage data and registrational pathways to watch.